A Phase 2, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Filgotinib in Subjects with Active Noninfectious Uveitis (Gilead)
- Sponsor: Gilead Sciences, Inc
- Principal Investigator: Laura Kopplin, MD, PhD
- Study Coordinator: Kelly Boyd
Study objective:
This study will compare filgotinib versus placebo for the treatment of the signs and symptoms of noninfectious uveitis.
Study design:
Patients will be randomly assigned to one out of two study treatment groups to receive filgotinib 200 mg once daily or placebo for up to 52 weeks.
Diagnosis and Key Eligibility Criteria:
Male or female subjects least 18 years or older with active, noninfectious intermediate-, posterior-, or pan-uveitis. Previous anti-VEGF treatment is allowed with a 90 day washout period from baseline.
Duration of study: Approximately 1 year.
For more information, contact Kelly Boyd 608-265-4589.